Moderna, Inc. (MRNA)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $77.78B
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Latest financial period: June 30, 2026
Filed with the SEC: July 31, 2026
Estimated earnings date: November 5, 2026
Profit #1374 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 5.5% | 5.4% | 6.1% | 7.3% |
Growth #1005 of 1484 companies
Payout #1117 of 1484 companies
Safety #894 of 1484 companies
Price #1389 of 1484 companies
